maintain outperform rate share gilead
scienc reduc price target follow
review result futur outlook result hcv
hiv franchis sale expect expect greater
stabil hcv trend go forward would note one-tim
inventori drawdown mask strong year-over-year growth
hiv product demand overal believ product trend support
guidanc trough earn return growth
see upsid potenti new growth driver includ cell
therapi product cancer phase nash trial broad
develop inhibitor filgotinib multipl larg immunolog
market base result guidanc reduc
non-gaap ep
report result yesterday market close
provid updat key initi non-gaap ep
lower consensu total revenu vs
consensu sequenti reiterate full
year guidanc net product sale
reflect season decreas inventori reduct
sub-wholesal hedg taf-bas biktarvi launch
avail gener viread tdf taf-bas regimen
compris prescript volum hiv
revenu europ total hiv/hbv sale decreas vs
decreas sale viread atripla
respect taf-bas singl tablet regimen genvoya
gild lead hiv therapi sale sequenti
gild newest taf-bas hiv regimen biktarvi
approv sale reflect spilt
switch nave patient expect biktarvi
becom gild lead hiv regimen nave switch
patient approv biktarvi eu expect
note biktarvi hiv switch sale deriv
genvoya remain gsk tivicay-
base regimen sale gild taf-bas regimen
odefsey descovi
increas decreas
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani prioriti stock list
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
hcv product sale versu consensu sequenti reflect
increas competit price pressur sale epclusa
sequenti sale gild three hcv therapi decreas sequenti
sale affect price decreas market share declin note hcv drug price
larg stabil market share expect stabil hcv
patient initi therapi expect patient start
continu declin slowli hcv remain signific opportun given larg number
untreat patient
sale yescarta ahead consensu current yescarta
treatment center train on-line enough addit center readi treat
on-label dlbcl patient current yescarta treat patient cover commerci
fee-for-servic insur cover medicar sever on-going yescarta trial
highlight first random control trial car-t therapi specif
compar yescarta salvag chemotherapi follow autolog stem cell transplant
line dlbcl expect cure rate control arm consid compani
leader cell therapi end recent sangamo collabor focu
develop off-the-shelf cell therapi product util sgmo gene edit modifi donor cell
allow safe use allogen product
term product develop pipelin note selonsertib inhibitor phase
stellar non-alcohol steatohepat nash trial complet enrol ahead expect
expect data patient fibrosi data fibrosi
potenti regulatori file combin selonsertib-with differ mechan
action fxr appear effect vs singl agent therapi anim model nash
recent easl meet present encourag reduct liver fat content marker
liver cell injuri week clinic trial includ selonsertib combin base data
patient studi initi evalu week treatment fxr
monotherapi selonsertib doublet combin therapi nash patient fibrosi
late expect data first filgotinib phase rheumatoid arthriti ra trial
enrol patient fail biolog therapi data finch trial
methotrex nave failur ra patient respect expect posit could
support regulatori file assess week filgotinib induct data
select ulcer coliti uc filgotinib trial posit trigger transit phase
filgotinib read-out includ phase data psoriat arthriti ankylos
price target
arriv price target appli multipl ep estim risk includ
continu slow hcv patient volum emerg credibl competit threat merck
particular failur key pipelin program hbv nash failur secur meaning revenu
opportun
expect stabil hcv trend visibl trough earn offset growth hiv product
emerg pipelin focus cell therapi cancer immunolog nash support out-performance
larg cap global commercial-stag biotechnolog compani discov develop small
molecul biolog drug global leadership hiv hcv expand beyond infecti
diseas liver diseas oncolog inflammation/fibrot diseas
